According to a statement from the company, the US District Court of Delaware issued the order based on a motion moved by AstraZeneca objecting to the usage of the colour purple in the generic version.
"The order has been passed pending further hearing of trial. The court has asked the parties to propose the next course of action and submit the same to the court. The court shall conduct a telephonic status conference on Thursday, November 12, 2015," the drugmaker said in the statement.
DRL launched the generic version of AstraZeneca's Nexium, used to treat acid reflux, in the US market on September 25.
Nexium and the generic had US sales of approximately USD 5.2 billion for the 12 months ended July 2015.